Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released a new report, "Type 1 Diabetes - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector.

Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest report, "Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016 " which provides the key data, information and analysis on the Parkinson's disease (PD) market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with Parkinson's disease, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the Parkinson's disease market.

Pulmonary Arterial Hypertension (PAH) - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest research, "Pulmonary Arterial Hypertension (PAH) - Pipeline Analysis and Market Forecasts to 2016", which provides key data, information and analysis on the PAH market. The report provides a comprehensive overview of the annualized market data from 2005 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs, competitive assessments, the product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the PAH market.

Dyslipidemia - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist's new report, "Dyslipidemia - Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest report, "HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016" which provides the key data, information and analysis on the HIV/AIDS market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with HIV/AIDS, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the HIV/AIDS market.

Biomarkers in Late-Stage Clinical Trials: Applications, opportunities and activities of leading players

Biomarkers reduce the attrition rate of late-stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of clinical trials, and help researchers complete the drug development process at a faster pace.

Depression - Generic induced brand erosion leads to market decline

The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosion due to generic incursion affecting all major drug classes used to treat depression finally outweighs the success of reformulations and follow-on products.

Antidepressants - Novel mechanism offers hope in depressed market

With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis's melatonin agonist and serotonin antagonist Valdoxan (agomelatine).

APA 2010: unmet needs in major depressive disorder remain key

Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.

The Cancer Market Outlook To 2014: Competitive landscape, market size, pipeline analysis and growth opportunities

Since 2000, oncology has become one of the most important growth segments among the pharmaceutical markets with a major focus on targeted agents. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in genomics, transcriptomics and proteomics.

Innovation and market growth opportunities in bone metastases and emerging supportive care challenges

Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies The supportive care market is potentially vast, therefore this report focuses on the cytopenias (anemia, neutropenia and thrombocytopenia), chemotherapy-induced nausea and vomiting, and bone metastases.

Future treatment will be based on individual tumor gene expression signatures

The majority of patients present with early-stage melanoma, when surgery is often curative. Patients with metastatic disease are poorly served by current drugs, with very few approved treatment options and no widely accepted standard of care. A significant unmet need therefore remains for more effective agents, which has made melanoma a popular R&D target.

ASCO 2010: ipilimumab achieves breakthrough in 'long dark tunnel' of metastatic melanoma

At this year's American Society of Clinical Oncology meeting, Bristol-Myers Squibb presented data for its monoclonal antibody ipilimumab in metastatic melanoma. Research and development in this area has been underwhelming over the past few years and, despite its high rate of adverse events, ipilimumab represents a breakthrough in the treatment of metastatic melanoma.

6th Annual

Pharma Marketing & Branding Excellence

25th - 26th January 2011., Milan, Italy

Following five successful annuals, Jacob Fleming Group invites you to the 6th Annual Pharma Marketing & Branding Excellence. Yet again we have gathered worldwide Pharma marketing specialists who will share their knowledge with you. Hear them speak about the most powerful marketing strategies and network face-to-face.  Come and listen to real life case studies, discover innovative approaches and benefit from interactive discussions with your peers to benchmark your experiences.

6th Annual

Project & Portfolio Management in the Pharmaceutical Industry

28th - 29th September 2010, Milan, Italy

What is the road to develop a strong portfolio to add value to key stakeholders?
How to deal with the risk in project & portfolio management to ensure optimal performance? This event will bring together the experts from the pharmaceutical industry to benchmark their best practices to enhance the innovation & create value in a current payer-driven and limited resources environment

Menzies Consulting, Inc. Publishes Article on Using Editorial Calendars

How-To Article Teaches C-Level Execs to Value Industry Media

 Devro Medical, Ltd. Continues Participation in Biomedical Industry Tradeshows Throughout 2010

 Growing demand for type I collagen spurs educational outreach at U.S., international events

Innovations in Injectables: Current and emerging technologies to improve drug delivery

This report evaluates the current and evolving technologies used for injectable drug delivery, the key therapuetic areas, the barriers and driving forces for this market, the competitive landscape is analysed according the technology type, and key pipeline companies and products are examined. Leading companies in the injectable drug delivery market are also profiled.